This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Stem Cell Research & Therapy Open Access 18 December 2021
-
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Molecular Cancer Open Access 19 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487–491.
Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.
Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST . Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716–5722.
Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 3130–3135.
Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105: 1652–1659.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dengler, J., von Bubnoff, N., Decker, T. et al. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 19, 1835–1838 (2005). https://doi.org/10.1038/sj.leu.2403848
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403848
This article is cited by
-
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Stem Cell Research & Therapy (2021)
-
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Molecular Cancer (2018)
-
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway
Oncogene (2010)
-
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
Leukemia (2007)